Abivax SA, a clinical-stage biotechnology company, has announced the pricing of its public offering of 10,156,000 American Depositary Shares (ADSs). Each ADS represents one ordinary share of the company and is priced at $64.00. The ADSs are listed on the Nasdaq Global Market under the ticker symbol "ABVX." Additionally, the ordinary shares are expected to be admitted for trading on Euronext in Paris. The offering is set to close on July 28, 2025, subject to customary closing conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.